Tempus Ai Class Stock Today
| TEM Stock | 54.91 2.47 4.71% |
PerformanceWeakest
| Odds Of DistressSmall
|
Tempus AI is selling at 54.91 as of the 6th of February 2026; that is 4.71 percent up since the beginning of the trading day. The stock's lowest day price was 52.96. Tempus AI has about a 26 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Note, on January 26, 2026, Representative Nancy Pelosi of US Congress acquired $50k to $100k worth of Tempus AI Class's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of June 2024 | Category Healthcare | Classification Health Care |
Tempus AI is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 172.86 M outstanding shares of which 21.4 M shares are at this time shorted by investors with about 4.3 days to cover. More on Tempus AI Class
Moving together with Tempus Stock
| 0.72 | A | Agilent Technologies Sell-off Trend | PairCorr |
Moving against Tempus Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Tempus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO, CoFounder | Eric Lefkofsky | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Tembo Gold Corp | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Nasdaq CTA Artificial, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Life Sciences Tools & Services, Internet Content & Information, Communication Services (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTempus AI utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Tempus AI's leverage profile, showing how much of Tempus AI's resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tempus AI Class (TEM) is traded on NASDAQ Exchange in USA and employs 2,400 people. Tempus AI is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 9.33 B. Tempus AI Class runs under Life Sciences Tools & Services sector within Health Care industry. The entity has 172.86 M outstanding shares of which 21.4 M shares are at this time shorted by investors with about 4.3 days to cover.
Tempus AI generates negative cash flow from operations
Check Tempus AI Probability Of Bankruptcy
Ownership AllocationTempus AI Class shows a total of 172.86 Million outstanding shares. Over half of Tempus AI's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that on January 26, 2026, Representative Nancy Pelosi of US Congress acquired $50k to $100k worth of Tempus AI Class's common stock.
Check Tempus Ownership Details
Tempus AI Historical Income Statement
Tempus Stock Against Markets
Tempus AI Corporate Management
| Ryan Fukushima | Chief Officer | Profile | |
| Stacey Kraft | Chief Officer | Profile | |
| Shane Colley | Chief Officer | Profile | |
| Patty Spiller | Senior Marketing | Profile | |
| Nike MD | Senior Pathology | Profile | |
| Christina Antoniou | Senior Development | Profile | |
| Ryan Bartolucci | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempus AI Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Will Life Sciences Tools & Services sector continue expanding? Could Tempus diversify its offerings? Factors like these will boost the valuation of Tempus AI. If investors know Tempus will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Tempus AI data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.29) | Revenue Per Share | Quarterly Revenue Growth 0.847 | Return On Assets | Return On Equity |
Investors evaluate Tempus AI Class using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Tempus AI's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Tempus AI's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Tempus AI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tempus AI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Tempus AI's market price signifies the transaction level at which participants voluntarily complete trades.